Research & Development
Agilent acquires Proscia for USD240m
4 November 2026 - Agilent Technologies Inc (NYSE: A), a provider of analytical and clinical laboratory technologies, announced on Wednesday that it has completed its acquisition of digital-pathology s...
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
4 November 2026 - Oncology company BeOne Medicines Ltd (Nasdaq: ONC) (HKEX: 06160) (SSE: 688235) reported on Wednesday that it has received US Food and Drug Administration (FDA) Priority Review for it...
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
4 November 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) announced on Wednesday that it has entered into an amended agreement with Arena Pharmaceuticals, a subsidiary of P...
Pentixapharm advances preparationsfor Phase 3 PANDA study
4 November 2026 - Biotechnology company Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) on Wednesday reported further progress towards its pivotal Phase 3 PANDA study, with US ethics approval ...
StimLabs launches DermaForm collagen scaffold particulate device
4 November 2026 - Regenerative medicine company StimLabs announced on Tuesday the commercial launch of DermaForm, an FDA 510(k)-cleared porcine-derived particulate collagen scaffold that manages a ran...
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evalua...